Qube Research & Technologies (QRT)’s Nurix Therapeutics NRIX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.64M	Sell	108,757 -376,455	-78%	-$6.41M	﹤0.01%	2005
2026 Q1	$7.52M	Buy	485,212 +459,223	+1,767%	+$7.61M	0.01%	1455
2025 Q4	$493K	Sell	25,989 -690,546	-96%	-$9.92M	﹤0.01%	2812
2025 Q3	$6.62M	Buy	716,535 +359,793	+101%	+$3.74M	0.01%	1581
2025 Q2	$4.06M	Buy	356,742 +61,995	+21%	+$670K	﹤0.01%	1832
2025 Q1	$3.5M	Sell	294,747 -58,724	-17%	-$982K	﹤0.01%	1719
2024 Q4	$6.66M	Buy	353,471 +138,743	+65%	+$3.18M	0.01%	1335
2024 Q3	$4.82M	Buy	214,728 +119,304	+125%	+$2.7M	0.01%	1405
2024 Q2	$1.99M	Buy	+95,424	New	+$1.49M	﹤0.01%	1628
2023 Q1	–	Sell	-11,179	Closed	-$123K	–	2870
2022 Q4	$123K	Buy	+11,179	New	+$135K	﹤0.01%	1951
2022 Q2	–	Sell	-33,003	Closed	-$462K	–	2930
2022 Q1	$462K	Buy	+33,003	New	+$586K	﹤0.01%	1570

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Qube Research & Technologies (QRT)'s NRIX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Nurix Therapeutics (NRIX) stake by 78% in Q2 2026, selling an estimated $6.41M and leaving 108,757 shares worth $2.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2005.

Qube Research & Technologies (QRT) first reported a position in NRIX in Q1 2022 and has held it in 11 quarters since. The position peaked at $7.52M in Q1 2026. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Qube Research & Technologies (QRT) held 108,757 shares of Nurix Therapeutics worth $2.64M as of Q2 2026.
Qube Research & Technologies (QRT) sold 376,455 Nurix Therapeutics shares in Q2 2026, an estimated $6.41M.
Nurix Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #2005 holding.
Qube Research & Technologies (QRT) first reported a position in Nurix Therapeutics in Q1 2022 and has held it in 11 quarters since.
Qube Research & Technologies (QRT)'s Nurix Therapeutics position peaked at $7.52M in Q1 2026.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.